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Abstract
Recently, we reported that the immediate-early (IE) protein of equine herpesvirus 1 (EHV-1) associates with transcription factor TFIIB
[J. Virol. 75 (2001), 10219]. In the current study, the IE protein purified as a glutathione-S-transferase (GST) fusion protein was shown to
interact directly with purified TFIIB in GST-pulldown assays. A panel of TFIIB mutants employed in protein-binding assays revealed that
residues 125 to 174 within the first direct repeat of TFIIB mediate its interaction with the IE protein. This interaction is physiologically
relevant as transient transfection assays demonstrated that (1) exogenous native TFIIB did not perturb IE protein function, and (2) ectopic
expression of a TFIIB mutant that lacked the IE protein interactive domain significantly diminished the ability of the IE protein to
trans-activate EHV-1 promoters. These results suggest that an interaction of the IE protein with TFIIB is an important aspect of the
regulatory role of the IE protein in the trans-activation of EHV-1 promoters.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Equine herpesvirus type 1 (EHV-1) is employed as a
model to study multiple aspects of herpesvirus infections,
including viral gene expression, persistent infection medi-
ated by defective interfering particles, and pathogenesis
(Frampton et al., 2002; O’Callaghan and Osterrieder, 1999;
Zhang et al., 2003). The EHV-1 genome is comprised of 78
genes that are coordinately regulated and temporally ex-
pressed as immediate-early (IE), early, late gamma-1, and
late gamma-2 genes (Caughman et al., 1985; Gray et al.,
1987a, 1987b), as is the case for other herpesviruses (Clem-
ents et al., 1977; Honess and Roizman, 1974; Roizman et
al., 1975; Weinheimer and McKnight, 1987). The coordi-
nated transcription of EHV-1 genes is regulated by six
regulatory proteins that are expressed as one IE protein, four
early proteins designated as EICP22, EICP27, EICP0, and
IR2, and one late protein, ETIF (Bowles et al., 1997, 2000;
Buczynski et al., 1999; Caughman et al., 1985, 1988; Der-
bigny et al., 2000, 2002; Gray et al., 1987a, 1987b; Grundy
et al., 1989; Harty and O’Callaghan, 1991; Harty et al.,
1990; Holden et al., 1995; Kim and O’Callaghan, 2001;
Kim et al., 1997; Lewis et al., 1993, 1997; Smith et al.,
1992, 1993, 1994, 1995; Zhao et al., 1992, 1995).
The IE protein (i) represses transcription from its own
promoter (Smith et al., 1992), (ii) potently activates expres-
sion of early EHV-1 promoters (Smith et al., 1992, 1995),
(iii) cooperates in a synergistic manner with the early
EICP22 and EICP27 proteins to trans-activate early and
some late promoters (Derbigny et al., 2000, 2002; Holden et
al., 1995; Kim et al., 1997; Smith et al., 1993; Zhao et al.,
1995), (iv) interacts physically with the EICP22 protein to
enhance the DNA-binding ability of the IE protein (Der-
bigny et al., 2000, 2002; Kim et al., 1997), and (v) exhibits
an antagonistic relationship with the early EICP0 protein, a
powerful and promiscuous trans-activator of all classes of
EHV-1 promoters (Bowles et al., 1997, 2000; Kim et al.,
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1999, 2003). An acidic trans-activation domain (TAD)
within the first 89 residues of the 1487 amino acid (aa) IE
protein is necessary for its regulatory functions (Smith et al.,
1994). In addition, aa 422 to 597 harbor a DNA-binding
domain that specifically binds to the consensus DNA se-
quence 5-ATCGT-3 (Kim et al., 1995). Depending on the
location of this consensus sequence relative to the transcrip-
tion initiation site, the IE protein either trans-activates or
represses transcription (Kim et al., 1995, 1999). Residues
963 to 970 contain an efficient nuclear localization signal,
which is necessary for the activation properties of the IE
protein (Smith et al., 1995).
The early IR2 protein is a truncated form of the IE
protein that lacks the acidic TAD and the serine-rich tract,
both of which are essential for IE protein function and virus
replication (Garko-Buczynski et al., 1998; Kim et al., 2001;
Harty and O’Callaghan, 1991; Smith et al., 1994). The
observation that the IR2 protein retains the DNA-binding
motif suggests that this protein functions as a negative
regulator of some EHV-1 promoters, including the IE pro-
moter (Kim et al., 1995; Smith et al., 1992).
General transcription factor TFIIB is a DNA-binding
protein that functions in multiple stages of transcription
(reviewed in Hampsey, 1998). The initial step in the for-
mation of a preinitiation complex is the assembly of the
TFIID–TFIIA (D–A) complex at the TATA box element
(reviewed in Hampsey, 1998). TFIIB next localizes to the
D–A complex via an interaction with TBP that is mediated
by TFIIB aa 178 to 201 within the first direct repeat (Bu-
ratowski and Zhou, 1993; Ha et al., 1993; Yamashita et al.,
1993) and stabilizes the interaction of the TATA box-bind-
ing protein (TBP) with the TATA box element (Gonzales-
Couto et al., 1997). Following recruitment of TFIIB to the
D–A complex, two TFIIB domains concomitantly engage
sequences surrounding the TATA box element (Bagby et
al., 1995; Nikolov et al., 1995). The TFIIB helix-turn-helix
motif spanning -helices 4 and 5 (aa 270 to 290) binds to
the TFIIB recognition element (BRE) that is immediately
upstream of the TATA box element and contains the con-
sensus sequence 5-C/C-G/C-G/A-C-G-C-C-3 (Lagrange
et al., 1998). Basic helices BH2 and BH3 spanning aa 133
to 170 interact with sequences downstream of and adjacent
to the TATA box element (Tsai et al., 2000). Localization of
TFIIB to promoters results in the recruitment of the RNA
polymerase II-TFIIF-TFIIH holoenzyme complex by a
mechanism that involves binding of TFIIB residues encom-
passing the zinc ribbon (aa 15 to 37) to RNA polymerase II
(Bangur et al., 1997, 1999; Bushnell et al., 1996; Hawkes
and Roberts, 1999; Kim et al., 1994; Koleske and Young,
1994; Ossipow et al., 1995; Pardee et al., 1998; Pinto et al.,
1994; Ranish et al., 1999; Thompson et al., 1993). The exact
manner by which the RNA polymerase II holoenzyme com-
plex is recruited to promoters remains unclear. The favored
model, however, involves the recruitment of a preassembled
holoenzyme complex that contains TFIIB to the D–A com-
plex (Gonzalez-Couto et al., 1997; reviewed in Koleske and
Young, 1995; Myer et al., 1998). TFIIB influences several
aspects of transcription initiation, and various viral regula-
tory proteins physically interact with TFIIB in a manner that
stimulates transcription of viral genes (Agostini et al., 1996;
Benson et al., 1997; Haviv et al., 1998; Rank and Lambert,
1995; Tong et al., 1995; Veschambre et al., 1997; Yao et al.,
1998).
Recently, we showed that the EHV-1 IE protein associ-
ates with TFIIB; however, it was not shown whether the
association of these two proteins resulted from a direct
interaction or required other cellular factors (Jang et al.,
2001). In this article, we employed purified IE and TFIIB
proteins to demonstrate that this interaction is direct. In
addition, a library of mutant forms of the TFIIB protein was
utilized to identify the TFIIB domain that mediates its
interaction with the IE protein. The physiological relevance
of this interaction was shown by transient transfection as-
says that demonstrated that the deletion of the IE protein-
binding domain within TFIIB greatly reduced (75%) the
ability of the IE protein to trans-activate EHV-1 promoters,
but did not have any inhibitory effect on VP16, a powerful
trans-activator encoded by herpes simplex virus 1.
Results
TFIIB directly interacts with GST-IEP (1–960)
Previous results showed that the EHV-1 IE protein as-
sociates with TFIIB in protein-binding assays (Jang et al.,
2001). To examine whether the IE protein directly interacts
with TFIIB, purified [glutathione-S-transferase (GST)-free]
TFIIB and GST-IE (1–960) were employed in GST-pull-
down assays. Western blot analyses of the precipitates with
an anti-TFIIB polyclonal antibody indicated that purified
GST-IE (1–960) directly precipitated TFIIB (Fig. 1, Lane
4). GST by itself, the negative control, was unable to pre-
cipitate the purified TFIIB protein (Fig. 1, Lane 3). Also, the
finding that the glutathione-Sepharose beads failed to pre-
Fig. 1. Direct interaction of GST-IE (1–960) with TFIIB. Precipitation of
TFIIB by GST-IE (1–960) in GST-pulldown assays was determined by
SDS–PAGE and Western blot analysis. The input lane (Lane 2) refers to
the amount of TFIIB included in each reaction. Western blot analysis with
the anti-TFIIB polyclonal antibody demonstrated the presence of TFIIB
within the precipitates (Lane 4). The sizes of the molecular weight markers
are indicated to the left.
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cipitate purified TFIIB (Fig. 1, Lane 3) indicated that the
GST moiety was absent from the recombinant TFIIB fol-
lowing its purification (see Materials and methods).
Identification of an IE protein-binding domain within
TFIIB
To map the IE protein-binding domain within TFIIB, a
panel of GST-TFIIB deletion and truncation mutants was
generated, purified, and employed in GST-pulldown assays
(Figs. 2A and B). The results of the initial GST-pulldown
assays involving [35S]methionine-labeled IE protein or IR2
protein are presented in Figs. 2C and D, respectively. GST-
TFIIB (1-316) interacted with both the in vitro transcribed/
translated (IVTT) IE and the IR2 proteins. The deletion
mutants GST-TFIIB4–37, GST-TFIIB4–66, GST-
TFIIB4–123, GST-TFIIB67–123, GST-TFIIB176–
201, GST-TFIIB202–269, GST-TFIIB271–297, GST-
TFIIB201–316, and GST-TFIIB271–316 precipitated
both the IE and the IR2 proteins with relatively the same
efficiency as did the full-length GST-TFIIB. However,
GST-TFIIB125–174 was not able to precipitate either of
the IVTT-synthesized EHV-1 proteins, suggesting that aa
125 to 174 within the first direct repeat of TFIIB contain an
IE protein-binding domain.
To confirm these mapping results, the ability of the panel
of GST–TFIIB fusion proteins to react with native IE pro-
tein present in EHV-1-infected murine cells was examined.
The binding reactions were performed with nuclear extracts
prepared from L-M cells mock-infected or infected for 6 h
with EHV-1 at an m.o.i. of 15 plaque forming units (PFU)
per cell. Native IE protein within each precipitate was de-
tected by Western blot analysis with an anti-IE polypeptide
polyclonal antibody (Smith et al., 1994). As was the case for
the IVTT-generated proteins, GST-TFIIB (1-316) interacted
with each of the four native IE protein species (Caughman
et al., 1988) from infected cell nuclear extracts, while GST-
TFIIB125–174 was incapable of precipitating any of the
Fig. 2. Deletion mutants of the GST-TFIIB fusion protein employed to map the IE protein-binding domain within TFIIB. (A) Schematic representation of
GST-TFIIB fusion proteins tested in protein-binding assays. The amino acid positions of the TFIIB functional domains are indicated at the top of the figure.
The amino acid sequence that is deleted in each TFIIB mutant is indicated to the left. (B) Coomassie blue-stained polyacrylamide gel of the E. coli expressed
GST-TFIIB fusion proteins. Molecular weight markers (kDa) are indicated on the left. (C) The GST-TFIIB proteins were assayed in GST-pulldown assays
for interaction with 35S-IE protein. (D) Parallel GST-pulldown assays tested the ability of the GST-TFIIB proteins to precipitate the 35S-IR2 protein. (E)
Interaction of TFIIB full-length and mutant GST-fusion proteins with the native IE protein from nuclear extracts of EHV-1-infected L-M cells. IE1 to IE4
represent a family of IE protein species that were characterized previously (Caughman et al., 1998). In C to E, input lanes represent the amount of IE or IR2
protein included in each reaction to assess the relative binding efficiency of each GST-TFIIB fusion protein.
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IE protein species (Fig. 2E). These results also indicate that
aa 125 to 174 within the first direct repeat of TFIIB harbor
an IE protein-binding domain. The inability of GST alone to
precipitate the test proteins indicated the specificity of the
GST-pulldown assays.
TFIIB aa 125–174 mediate binding to the IE protein
To confirm that aa 125 to 174 of TFIIB specifically
interact with the IE and IR2 proteins, the ability of different
forms of the IE protein produced as GST fusion proteins to
precipitate [35S]methionine-labeled TFIIB or TFIIB125–
174 was examined (Fig. 3). We previously reported that aa
407–757 of the IE protein are important for its association
with TFIIB (Jang et al., 2001). Therefore, GST-IE (407–
757) was included in these experiments to demonstrate that
this sequence is sufficient to mediate a direct interaction
with TFIIB. As shown in Fig. 3, GST-IE (1–1487), GST-
IR2 (323–1487), and GST-IE (407–757) precipitated full-
length, 35S-labeled TFIIB with equal efficiency, indicating
that IE aa 407–757 participate in the direct interaction with
TFIIB. 35S-TFIIB125–174 that lacks the putative IE pro-
tein interactive domain failed to bind to any of these three
GST-IE fusion proteins. These results are in agreement with
the mapping data in Fig. 2 and indicate that the IE protein-
binding domain maps to aa 125 to 174 within the first direct
repeat of TFIIB.
To identify conclusively the IE protein-binding domain,
additional GST-TFIIB mutants (Fig. 4A) were examined for
an interaction with the 35S-IE protein. In this experiment,
the two GST-TFIIB proteins that contain the IE protein-
binding domain within aa 125 to 174 interacted efficiently
with 35S-IE (Fig. 4B). However, the two TFIIB proteins that
lack aa 125 to 174, GST-TFIIB (1–123) and GST-TFIIB
(175–316), were incapable of precipitating the IE protein.
Thus, the EHV-1 IE protein interacts with this cellular
transcription factor, and a domain of the IE protein within aa
407 to 757 directly interacts with TFIIB residues 125 to 174.
TFIIB125–174 does not perturb the expression of the IE
gene
Before assessing the effect the mutant forms of TFIIB
exert on IE gene function, it was important to show that
ectopically expressed TFIIB species did not alter the syn-
thesis of the IE protein. L-M cells were cotransfected with
the pSVIE expression construct and either the TFIIB (1–
316) or the TFIIB125–174 expression construct. Cell ly-
sates were prepared 48 h posttransfection, and Western blot
analyses that employed IE polypeptide-specific antiserum
were performed to determine whether the different forms of
the TFIIB proteins influenced the steady-state levels of the
IE protein (Fig. 5). The internal control was a cellular
protein that was nonspecifically detected by the anti-IE
polypeptide antibody (Jang et al., 2001) and indicated that
each sample contained an equal amount of protein. Com-
pared to the steady-state level of the IE protein in cells
transfected with just the pSVIE expression construct (Fig. 5,
Lane 3), neither the expression of TFIIB (1–316) nor
TFIIB125–174 adversely affected IE protein synthesis
(Fig. 5, Lanes 5 and 6, respectively), indicating that the
mutant form of TFIIB does not down-regulate the constitu-
tively active SV40 promoter or adversely affect IE protein
Fig. 3. TFIIB amino acids 125 to 174 physically interact with the IE protein
in a GST-pulldown assay. Input lanes represent the amount of 35S-TFIIB or
35S-TFIIB125–174 included in the reactions, which were employed to
assess the relative binding efficiency of each GST fusion protein.
Fig. 4. Protein–protein interaction assays confirmed that amino acids 125 to 174 of TFIIB harbor the minimal IE protein-binding domain. (A): Coomassie
blue stained polyacrylamide gel of the E. coli expressed GST-TFIIB fusion proteins. (B): GST-pulldown assay assessed the ability of the GST fusion proteins
to interact with the 35S-IE protein. The input lane represents the amount of 35S-IE protein included in each reaction and was employed to assess the relative
binding efficiency of each GST fusion protein. In both panels, molecular weight markers (kDa) are indicated on the left.
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stability. As a negative control for the specificity of the
anti-IE polypeptide antibody, cell lysates were prepared
from cells transfected with the empty pSV-Sport 1 expres-
sion construct (Fig. 5, Lane 2). Additionally, cotransfection
of the empty pTriEx-1 vector with the pSVIE construct also
did not interfere with the synthesis of the IE protein (Fig. 5,
Lane 4).
Importance of the interaction between the IE protein and
TFIIB
To ascertain whether the interaction between TFIIB and
the IE protein is essential for full activity of the IE protein
as a trans-activator, transient transfection assays were car-
ried out in murine fibroblast cells. As shown in Fig. 6, the
IE protein significantly activated the EHV-1 early EICP27
promoter greater than four-fold over basal levels observed
for the EICP27 promoter alone (Fig. 6, Bar 2), which is
consistent with our previously published findings (Bowles
et al., 1997, 2000; Kim et al., 1997, 1999; Smith et al., 1992;
Zhao et al., 1995). Expression of native TFIIB from trans-
fected pTriExTFIIB (1–316) increased the level of chlor-
amphenicol acetyl transferase (CAT) activity greater than
three-fold over the basal level (Fig. 6, Bar 3). This obser-
vation suggests that although the level of endogenous TFIIB
was sufficient for promoter activity, the amount of endog-
enous TFIIB was limiting for maximal transcription from
the EICP27 promoter. Increasing amounts of native TFIIB
significantly increased the ability of the IE protein to trans-
activate the EICP27 promoter (P  0.005; Fig. 6, Bars 4 to
6). The expression of TFIIB125–174 enhanced the basal
expression of the EICP27 promoter (Fig. 6, Bar 7). In
marked contrast, the regulatory function of the IE protein
was proportionately decreased in the presence of increasing
molar concentrations of plasmid TriExTFIIB125–174 that
expresses TFIIB lacking the IE protein interactive domain
(Fig. 6, Bars 8 to 10). The trans-activation function of the IE
protein was decreased by more than 65% when 0.4 pmol of
pTriExTFIIB125–174 was cotransfected with the IE ex-
pression construct (Fig. 6, Bar 10, P  0.005). Similar
results were observed with the early viral thymidine kinase
(TK) promoter-CAT reporter construct (data not shown), in
that expression of TFIIB lacking the IE protein interactive
domain significantly reduced trans-activation of this EHV-1
promoter by 70%. These results suggested that the interac-
Fig. 5. The steady-state level of the IE protein was not reduced by
overexpression of TFIIB125–174. Murine fibroblast L-M cells were
transfected with 0.3 pmol of the pSVIE expression plasmid in the absence
or presence of 0.4 pmol of either the parental cloning vector (pTriEx-1)
(lane 4) or the plasmids expressing native TFIIB (1–316) (Lane 5) or
TFIIB125–174 (Lane 6). As a negative control, the cells were transfected
with the parental expression vector pSV-Sport1 (Lane 2), which was
employed to clone the IE gene. Western blot analyses with an anti-IE
polypeptide-specific antibody were performed as described under Materials
and methods.
Fig. 6. Deletion of the IE protein-binding domain within TFIIB reduces the
ability of the IE protein to trans-activate the EHV-1 early EICP27 pro-
moter. Transient transfection assays employing the EICP27-CAT reporter
were performed to test the effect of ectopically expressed full-length TFIIB
or TFIIB125–174 on the regulatory activity of the IE protein. L-M cells
were transfected with 1.4 pmol of the pEICP27-CAT reporter (pEICP27-
CAT) alone (Bar 1) or were cotransfected with pEICP27-CAT and one of
the effector constructs (Bars 2 to 10). pSVIE was cotransfected at 0.3 pmol
per transfection (Bars 2, 4, to 6, and 8 to 10). pSVIE was cotransfected with
increasing molar concentrations of 0.1, 0.2, or 0.4 pmol of pTriExTFIIB
(1–316) (Bars 4 to 6, respectively). pSVIE was cotransfected with increas-
ing molar concentrations of 0.1, 0.2, or 0.4 pmol of pTriExTFIIB125–174
(Bars 8 to 10, respectively). The data are representative of four independent
experiments in which each sample was assayed independently in triplicate.
The error bars show the standard deviations. * denotes statistical signifi-
cance (P  0.005) when the CAT activity of a sample was compared to the
CAT activity achieved when cells were transfected with pEICP27-CAT
and pSVIE.  denotes statistical significance (P  0.005) when the CAT
activity of a sample was compared to the CAT activity achieved when cells
were transfected with pEICP27-CAT in the absence of any vectors encod-
ing effector proteins.
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tion of TFIIB with the IE protein is important for the IE
protein to maximally trans-activate EHV-1 promoters.
TFIIB125–174 specifically attenuates trans-activation by
the IE protein
Overexpression of TFIIB125–174 might not specifi-
cally perturb the regulatory function of the IE protein, but
instead this TFIIB mutant may be intrinsically defective in
participating in basal as well as activator-dependent tran-
scription. This possibility was explored in the Gal4 two-
plasmid transient transfection assay that included the 78 aa
trans-activation domain of VP16 from herpes simplex virus
type 1, synthesized as a Gal4 fusion protein (Gal4-
VP16TAD; Smith et al., 1994). The VP16 TAD stimulates
the formation of a preinitiation complex by multiple mech-
anisms that include a direct interaction with a region of
TFIIB that encompasses its second basic repeat (aa 175–
200; Chou and Struhl, 1997; Lin et al., 1991; Roberts et al.,
1993). As presented in Fig. 7, Gal4-VP16TAD significantly
stimulated transcription from the Gal4-responsive promoter
as indicated by a significant increase in CAT reporter ac-
tivity (Fig. 7, Bar 2, P  0.005). Contrary to results ob-
tained with the EHV-1 EICP27 promoter, ectopic expres-
sion of either TFIIB (1–316) or TFIIB125–174 did not
result in any activation of the G5EC promoter (Fig. 7, Bars
3 and 6, respectively). Increasing the amount of ectopically
supplied TFIIB (1–316) potentiated trans-activation of the
G5EC promoter by the Gal4-VP16TAD fusion protein (Fig.
7, Bars 4 and 5). Specifically, when 0.4 pmol of TFIIB
(1–316) was employed (Fig. 7, Bar 5), VP16 trans-activa-
tion of the G5EC promoter was significantly increased (P 
0.005). In contrast to the negative effects of TFIIB125–
174 on the regulatory function of the IE protein (Fig. 6, Bar
10), cotransfection of the pGal4-VP16TAD expression vec-
tor with 0.4 pmol of the plasmid TriExTFIIB125–174 did
not have an inhibitory effect on VP16 function; indeed, a
reproducible increase in VP16 trans-activation of the G5EC
promoter was observed (Fig. 7, Bar 8). These data indicate
that the TFIIB125–174 mutant is specifically defective in
participating in IE protein-mediated activation of EHV-1
promoters. The results of Figs. 6 and 7 reveal that ectopic
expression of a mutant TFIIB protein that lacks sequences
that mediate an interaction with the IE protein, but not with
VP16, selectively fails to allow maximal trans-activation by
the IE protein. Overall, these data indicate that the physical
interaction of the IE protein with TFIIB plays an important
role in viral gene expression.
Discussion
Previously, we presented evidence that residues 407 to
757 within the IE protein’s helix-loop-helix motif associate
with TFIIB during viral infection (Jang et al., 2001). The
EHV-1 IE protein trans-activates viral promoters by ac-
tively recruiting components of the RNA polymerase II
preinitiation complex to promoters, a mechanism shared by
other alphaherpesvirus regulatory proteins. HSV-1 VP16,
an essential activator of immediate-early promoters, binds
to multiple components of the preinitiation complex (Hall
and Struhl, 2002), including direct interactions with TFIIB
(Chou and Struhl, 1997; Lin et al., 1991; Roberts et al.,
1993), TBP (Ingles et al., 1991; Stringer et al., 1990),
TAFII32 (Klemm et al., 1995), and TFIIA (Kobayashi et al.,
1995). In addition, HSV-1 ICP4 stimulates transcription
from late promoters via interactions with TFIID in a manner
that is dependent on an additional interaction with TAFII250
(Carrozza and DeLuca, 1996; Grondin, 2000; Gu and De-
Luca, 1994).
In this article, we determined that there is a direct inter-
action between TFIIB and this major EHV-1 regulatory
protein, and that aa 125 to 174 in TFIIB harbor the IE
protein interactive domain. Our previous work with the
yeast II hybrid system revealed that the IE protein interacts
with itself to form dimers (Derbigny et al., 2000). This
dimerization of the IE protein, possibly via its helix-loop-
helix motif, exposes key hydrophobic residues that enable
the IE protein to interact with TFIIB. The TFIIB residues
Fig. 7. Ectopic expression of a TFIIB mutant that lacks the IE protein
interactive domain does not inhibit the trans-activation function of VP16.
Gal4 two-plasmid assays employing the Gal4-responsive promoter pG5EC
were performed to determine whether TFIIB125–174 participated nor-
mally within preinitiation complexes directed by the VP16 TAD. In each
sample, L-M cells were transfected with at least 0.5 pmol of the pG5EC
reporter (Bars 1 to 8). pGal4-VP16TAD was transfected at 0.1 pmol per
transfection (Bars 2 to 8). pTriExTFIIB (1–316) and pTriExTFIIB125–
174 were individually transfected at 0.4 pmol (Bars 3 and 6, respectively).
pGal4-VP16TAD was cotransfected with increasing molar concentrations
of 0.1 or 0.4 pmol of either pTriExTFIIB (1–316) (Bars 4 and 5) or
pTriExTFIIB125–174 (Bars 7 and 8). The data are representative of four
independent experiments in which each sample was assayed independently
in triplicate. The error bars show the standard deviations. * denotes statis-
tical significance (P  0.005) when the CAT activity of a sample was
compared to the CAT activity achieved when cells were transfected with
pG5EC and pGal4-VP16TAD.  denotes statistical significance (P 
0.005) when the CAT activity of a sample was compared to the CAT
activity achieved when cells were transfected with pG5EC in the absence
of any vectors encoding effector proteins.
307R.A. Albrecht et al. / Virology 316 (2003) 302–312
(aa 125 to 174) that associate with the IE protein are located
within the first direct repeat of TFIIB. Residues 159 to 168
of the first direct repeat of TFIIB are rich in hydrophobic
amino acids (Bagby et al., 1995). Thus, the interaction of
these two proteins appears to be mediated by hydrophobic
domains, which is consistent with our previous hypothesis
(Jang et al., 2001). The mapping of the IE protein-binding
domain within this core supports our suggested mechanism
by which the IE protein interacts with both DNA and TFIIB
(Jang et al., 2001). The demonstration that the IR2 protein
binds to this TFIIB domain with an efficiency comparable to
that of the IE protein raises an interesting possibility. Since
the IR2 protein lacks the potent acidic trans-activation do-
main within aa 3 to 89 of the full-length IE protein, the IR2
protein may function as a negative regulator of viral gene
expression by squelching the limited supply of transcription
factors such as TFIIB.
Transient transfection assays provided two observations
concerning the in vivo importance of the TFIIB-IE protein
interaction with respect to EHV-1 promoter trans-activa-
tion. First, ectopically supplied native TFIIB enhanced the
basal levels of transcription initiated from the EICP27 pro-
moter (greater than a three-fold increase in the presence of
0.4 pmol of the native TFIIB expression construct) and
augmented the regulatory function of the IE protein (ap-
proximately a 51% increase). Second, and a more signifi-
cant observation, exogenously supplied mutant TFIIB lack-
ing the domain that mediates its interaction with the IE
protein selectively impaired the trans-activation function of
the IE protein (approximately a 65% decrease in the pres-
ence of 0.4 pmol of the mutant TFIIB125–174 expression
construct). In these assays, TFIIB125–174 increased the
basal level of transcription from the EICP27 promoter by
approximately 83% (Fig. 6, lane 7). This observation indi-
cated that the mutant TFIIB was still capable of interacting
with components of the preinitiation complex, resulting in
the increased basal transcription from this viral promoter.
We speculate that the impaired regulatory function of the IE
protein in the presence of this mutant TFIIB results from
competition of mutant TFIIB and wild-type TFIIB for bind-
ing to RNA polymerase II, which ultimately reduces the
recruitment of RNA polymerase II to viral promoters. Fur-
thermore, the ability of the TFIIB mutant to augment the
regulatory function of the VP16 TAD suggests that this
mutant protein retains activities that are necessary for it to
function properly within the preinitiation complex. This
observation supports our notion that the diminished regula-
tory function of the IE protein is a result of an absence of
necessary protein–protein interactions between the IE pro-
tein and TFIIB, and not of improper function of the TFIIB
mutant. These interpretations are supported by the revela-
tion that overexpression of TFIIB125–174 did not nega-
tively influence the steady-state levels of the IE protein
during the duration of the transient transfection assays.
The ability of TFIIB125–174 to enhance gene expres-
sion in our assays is in agreement with other findings in
which overexpressed TFIIB148–163 increased reporter
expression controlled by the human immunodeficiency vi-
rus type 1 long terminal repeat (LTR) (Veschambre et al.,
1997). Collectively, these data suggest that TFIIB125–174
is competent for activator-independent initiation of tran-
scription from the heterologous promoters tested in these
experiments. The failure of exogenously provided
TFIIB125–174 to block completely the trans-activation
function of the IE protein could be explained by insufficient
quantities of TFIIB125–174 to outcompete the endoge-
nous TFIIB, which was present in levels sufficient to allow
formation of preinitiation complexes that support activated
transcription of EHV-1 genes.
Overall, these data support our assumption that the in-
teraction of the IE protein with general transcription factor
TFIIB is necessary for the trans-activation properties of the
IE protein (Jang et al., 2001). However, the mechanism(s)
by which the acidic trans-activation domain (aa 3 to 89)
influences transcription remains obscure. In addition, IE
protein residues 1029 to 1487 appear to possess a domain(s)
that enhances the regulatory function of the IE protein by an
unknown mode of action (Buczynski et al., 1999; Smith et
al., 1994). Future endeavors will involve ascertaining
whether these domains within the IE protein interact with
other transcription factors and/or RNA polymerase II in a
fashion that facilitates the formation of preinitiation com-
plexes at EHV-1 promoters and/or stimulates elongation of
transcribing RNA polymerase II holoenzyme complexes.
Materials and methods
Plasmid construction
To facilitate the mapping of the domain of TFIIB that
mediates its interaction with the IE protein, a panel of
GST-TFIIB deletion mutants was constructed (Fig. 1A).
Plasmid GSTKG-TFIIB, which contains the entire TFIIB
coding sequence cloned in-frame with the GST gene and
expresses the fusion protein GST-TFIIB (1–316), was de-
scribed previously (Jang et al., 2001). Digesting pGBK-
TFIIB with SmaI and SalI, and ligating the released TFIIB
gene to pGEX-4T1 (Promega, Madison, WI) that was di-
gested with SmaI and SalI, generated plasmid GST4T1-
TFIIB. Plasmid GST-TFIIB4–37 was generated by a two-
step cloning strategy. First, pGSTKG-TFIIB was digested
with AccI and SalI, followed by blunt-ending the 5 end
with Klenow enzyme, and inserting a ClaI linker d(pC-
CCATCGATGGG) (New England Biolabs, Beverly, MA)
at codon 4 to generate pGSTKG-TFIIBaa4C. Plasmid
GSTKG-TFIIBaa4C was subsequently digested with ClaI
and HindIII and ligated with a PCR-amplified segment of
TFIIB spanning codons 38 to 311. The forward primer
was 5-CCATCGATGGCTTGGTTGTAGGTGACCGGG-3
and the reverse primer was 5-CCCAAGCTTTTATAGCT-
GTGGTAGTTTGTC-3. GST-TFIIB4–66 is a derivative
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of pGSTKG-TFIIBaa4C. Plasmid GSTKG-TFIIBaa4C was
digested with ClaI and HindIII and ligated with a PCR-
amplified segment of TFIIB spanning codons 67 to 311. The
forward primer was 5-CCATCGATGTTGGAGATTCT-
CAGAATCCTC-3 and the reverse primer was 5-
CCCAAGCTTTTATAGCTGTGGTAGTTTGTC-3. Plas-
mid GST-TFIIB4–123 is a subclone of pGSTKG-
TFIIBaa4C and was generated by inserting a PCR-amplified
segment of TFIIB corresponding to codons 124 to 311. The
forward primer was 5-CCATCGATATGGCAGACA-
GAATCAATCTAC-3 and the reverse primer was 5-
CCCAAGCTTTTATAGCTGTGGTAGTTTGTC-3. Plas-
mid GST-TFIIB67–123 was derived from pGST4T1-
TFIIBaa67N, which was generated by partially digesting
pGST4T1-TFIIB with XhoI, blunt-ending the 5 end, and
inserting the NcoI linker d(pCCCATGGG) (New England
Biolabs) at codon 67. Plasmid GST4T1-TFIIBaa67N was
subsequently digested with NcoI and religated to generate
pGST-TFIIB67–123. Plasmid GST-TFIIB125–174 was
derived from pGSTKG-TFIIBaa174N, which was generated
by digesting pGSTKG-TFIIB with AvrII, blunt-ending the
5 end, and inserting the NcoI linker d(pCAGCCATG-
GCTG) (New England Biolabs). Plasmid GSTKG-
TFIIBaa174N was subsequently digested with NcoI and
religated to generate pGST-TFIIB125–174. Plasmid GST-
TFIIB176–201 was generated by digesting pGSTKG-
TFIIB with AvrII and Eco47III, blunt-ending the 5 end with
Klenow enzyme, and religating the resulting DNA frag-
ment. Plasmid GST-TFIIB202–269 was cloned by digest-
ing pGSTKG-TFIIB with Eco47III and PpuMI, blunt-end-
ing the 5 end, and religating the resulting DNA fragment.
Plasmid GST-TFIIB271–297 was derived from pGSTKG-
TFIIBaa270B, which was cloned by digesting pGSTKG-
TFIIB with PpuMI, blunt-ending the 5 end, and inserting
the BglII linker d(pGGAAGATCTTCC) (New England
Biolabs). Plasmid GSTKG-TFIIBaa270B was subsequently
digested with BglII and religated to generate pGST-
TFIIB271–297. Plasmid GST-TFIIB201–316 was
cloned by digesting pGSTKG-TFIIB with Eco47III and
HindIII, blunt-ending the 5 end, and religating the resulting
DNA fragment. Plasmid GST-TFIIB271–316 was cloned
by digesting pGSTKG-TFIIB with PpuMI and HindIII,
blunt-ending the 5 end, and religating the resulting DNA
fragment. pGST-TFIIB (1–123) was created by digesting
pGSTKG-TFIIB with NcoI and HindIII, filling in the 5
overhang with Klenow enzyme, and self-ligating the DNA
fragment. pGST-TFIIB (67–200) was cloned by digesting
pGST-TFIIB4–66 with Eco47III and HindIII, and self-
ligating the resulting Klenow-treated restriction enzyme
fragment. pGST-TFIIB (175–316) was generated by cutting
pGST-TFIIB4–66 with ClaI and AvrII and self-ligating
the resulting Klenow-treated restriction enzyme fragment.
Plasmids pGST-IE, pGST-IR2 (323–1487), pGST-IE (1–
960), and pGST-IE (407–757), which express IE aa 1 to
1487, 323 to 1487, 1 to 960, and 407 to 757 as GST fusion
proteins, respectively, were discussed previously (Jang et
al., 2001; Kim et al., 1995).
The mammalian expression plasmids pSVIE and pTriEx-
TFIIB (1–316) that encode the full-size IE protein and the
full-size TFIIB, respectively, were described previously
(Smith et al., 1992; Jang et al., 2001). The plasmid pTriEx-
TFIIB125–174 was generated by subcloning a BstEII/
BglII fragment of pGST-IIB125–174 into pTriExTFIIB
(1–316) digested with BstEII and BglII. pTriExTFIIB1–
123 was created by PCR amplification of the TFIIB se-
quence that spanned codons 124 to 311. The forward primer
was 5-CCATCGATATGGCAGACAGAATCAATCTAC-3
and the reverse primer was 5-CCCAAGCTTTTATAGCT-
GTGGTAGTTTGTC-3. The resulting PCR product was
digested with HindIII and then ligated with SmaI/HindIII-
digested pGST-Kg.
In vitro transcription/translation
pG3IE and pGEM44, which express IE (1–1487) and IE
(323–1487; IR2 protein), respectively, from the Sp6 pro-
moter in IVTT reactions employing the TNT coupled rabbit
reticulocyte lysate system (Promega) were described previ-
ously (Harty and O’Callaghon, 1991; Jang et al., 2001).
Plasmid pG3TFIIB, which expresses the entire TFIIB gene
in IVTT reactions, was described earlier (Jang et al., 2001).
Plasmid G3TFIIB125–174 was expressed in IVTT reac-
tions to generate TFIIB125–174. Plasmid G3TFIIB125–
174 was generated by cloning the BstEII–BglII fragment of
pGST-TFIIB125–174 into the BstEII-BglII sites of
pG3TFIIB (1–316).
Purification of GST-fusion proteins
The GST-TFIIB expression plasmids (Fig. 2A) were
transformed into Escherichia coli (BL21DE3LysE) cells.
GST fusion protein synthesis was induced by culturing the
transformed bacteria for 1.5 to 2 h at 37°C in 2 YT
medium supplemented with 0.5 mM isopropyl--D-thiogal-
actoside (IPTG) as described previously (Jang et al., 2001;
Kim et al., 1995, 1997). The soluble GST fusion proteins
were purified with the GST Bind Kit as described earlier
(Novagen, Madison, WI; Jang et al., 2001). Briefly, bacteria
were lysed in the BugBuster Protein Extraction Reagent; the
insoluble debris was removed by centrifugation, and the
soluble GST fusion proteins were batch-purified using the
GST-Bind Resin. The eluted GST fusion proteins were then
filtered through Centricon columns (Amicon, Millipore,
Bedford, MA) as directed by the manufacturer to both desalt
and concentrate the purified proteins. The eluted proteins
were next separated by SDS–PAGE and visualized by stain-
ing the gel with Coomassie blue (Fig. 2B). The quantity of
each fusion protein was determined with the Gel Doc 1000/
2000 gel documentation system (Bio-Rad, Hercules, CA) by
densitometric comparison of each fusion protein with
known amounts of bovine serum albumin. GST-free TFIIB
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was generated by incubating 1 g of GST-TFIIB fusion
protein with 1 cleavage unit of thrombin (Sigma Chemical,
St. Louis, MO) for 4 h at room temperature. The GST
moiety was then removed from the TFIIB preparation by
incubating the reaction with GST Bind Resin for 1 h at room
temperature.
In vitro interaction assays
Two micrograms of each GST-TFIIB protein was incu-
bated with [35S]methionine-labeled IE protein or IR2 pro-
tein for 1 h at room temperature in binding buffer (100 mM
NaCl, 1 mM EDTA, 20 mM Tris-HCl [pH 8.0], and 0.5%
NP-40). The GST fusion protein complexes were then pre-
cipitated with a 50% slurry of glutathione-Sepharose beads
(Pharmacia, Piscataway, N.J.) for 1 h at room temperature.
After washing the resin five times with binding buffer, the
presence of precipitated 35S-IE protein or 35S-IR2 protein in
each sample was assessed by SDS–PAGE and autoradiog-
raphy (Jang et al., 2001). For protein-binding assays involv-
ing purified TFIIB or EHV-1-infected cell extracts, the
identities of the precipitated proteins were assessed by
SDS–PAGE and Western blot analyses (Jang et al., 2001).
Western blot analysis and antibodies
Precipitated proteins were resolved in SDS–PAGE gels
and electrotransferred to a nitrocellulose membrane (Bio-
Rad) for 1 h. After transfer of the proteins, the membrane
was blocked for 30 min at RT in TBST buffer containing
5% nonfat powdered milk. The membranes were then incu-
bated for 1 h at RT with either anti-TFIIB rabbit polyclonal
antibody (SI-1, Santa Cruz Biotechnology, Santa Cruz, CA)
or anti-IE polypeptide antibody (Jang et al., 2001; Smith et
al., 1994). The antibodies were diluted 1:1000 in TBST
buffer (10 mM Tris–HCl [pH 8.0], 150 mM NaCl, 0.05%
Tween 20). The membrane was then washed three times
consecutively for 10 min per wash with TBST before incu-
bating the membrane with alkaline phosphatase conjugated
goat anti-rabbit antibody (Sigma) diluted 1:10,000 in TBST
for 1 h at RT. The membrane was washed once with TBST
and subsequently washed twice with AP buffer (100 mM
Tris–HCl [pH 9.5], 100 mM NaCl, and 5 mM MgCl2).
Finally, the precipitated TFIIB was visualized by incubating
the membrane in AP buffer supplemented with 0.165 mg of
5-bromo-4-chloro-3-indolylphosphate p-toluidine salt (BCIP)
per milliliter and 0.3 mg of nitroblue tetrazolium chloride
(NBT) per milliliter (Invitrogen, Carlsbad, CA).
Chloramphenicol acetyltransferase (CAT) assays
Methods for CAT assays that employed the EHV-1
EICP27 promoter-CAT chimera reporter (pEICP27-CAT)
have been described elsewhere (Smith et al., 1992; Zhao et
al., 1995). The Gal4 two-plasmid assay as well as the
expression vector for Gal4-VP16TAD and the Gal4 promot-
er-CAT reporter construct (pG5EC) were described previ-
ously (Smith et al., 1994). Murine fibroblast L-M cells were
cultured as monolayers in Eagle’s minimum essential me-
dium (EMEM) supplemented with penicillin (100 g/ml),
streptomycin (100 g/ml), nonessential amino acids, and
5% fetal bovine serum (FBS) (Jang et al., 2001; Smith et al.,
1992).
L-M fibroblast cells cultured on 60-mm tissue culture
dishes (2  106 cells per dish) were transfected with plas-
mid DNA–liposome complexes generated with lipofectin
(Invitrogen). Cells were transfected with 1.4 pmol of the
pEICP27-CAT reporter. The constructs pSVIE, pTriEx
TFIIB (1–316), pTriExTFIIB125–174, pEICP27-CAT,
pGal4-VP16TAD, and pG5EC were transfected in molar
amounts as indicated in the figure legends. For each trans-
fection, the total amount of DNA transfected per triplicate
of plates was adjusted to 20 g by addition of pUC19 DNA.
At 48 to 50 h after transfection, the cells were harvested,
and total cell lysates were prepared essentially as described
(Bowles et al., 1997, 2000; Kim et al., 1997, 1999; Smith et
al., 1992). Each CAT assay was independently repeated at
least three times, and within individual experiments, each
sample was assayed in triplicate. The data were analyzed for
statistical significance by the Student’s t test.
TFIIB125–174 was compared to TFIIB (1–316) for
adverse effects on the steady-state levels of the IE protein
by Western blot analyses. L-M fibroblast cells cultured on
60-mm tissue culture dishes (2  106 cells per dish) were
transfected with 0.3 pmol of pSVIE and 0.4 pmol of either
pTriEx-1, pTriExTFIIB (1–316), or pTriExTFIIB125–
174. Forty-eight hours posttransfection, the cells were lysed
in lysis buffer [250 mM Tris–HCl [pH 8.0], 50% M-Per
(Pierce, Rockford, IL)], and 40 g of cell lysate was pro-
cessed for Western blot analysis with the anti-IE polypep-
tide antibody as described above.
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